CD70 and nonpapillary renal cell carcinoma: MDX‐1203, another CD70‐targeted ADC comprising a fully human antibody and a duocarmycin‐derived cytotoxic payload, entered a phase I study (NCT00944905) involving 26 patients diagnosed with ccRCC or B‐cell NHL.